Huge demand for exposure to biotech companies among US equity investors is continuing to drive UK firms to list on the other side of the Atlantic through an IPO on the Nasdaq. On Thursday, Immunocore, a late-stage biotech firm focused on T-cell technology, priced an enlarged offering on the exchange and, on Friday, UK healthcare investor Syncona announced it was exploring a US IPO for one of its portfolio companies.
Recent Comments